10 Best Nasdaq Stocks Under $5 to Buy
The Nasdaq is one of the top three most-followed stock market indices in the United States, comprising over 2,500 stocks.
Arbutus Biopharma Corp (ABUS)
Market is closed
Sector: Pharmaceutical Preparations
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Whitefort Capital David Salanic | 13,241,916 | $43,301,065 | +3% | 20.72% |
| 2. | Two Seas Capital Sina Toussi | 8,740,956 | $28,582,926 | +5% | 2.46% |
| 3. | Blackbarn Capital Jonathan Carter | 2,341,871 | $7,657,918 | +14% | 0.42% |
| 4. | Rubric Capital Management David Rosen | 1,681,090 | $5,497,164 | 0.07% | |
| 5. | Adage Capital Management Phill Gross And Robert Atchinson | 1,650,941 | $5,398,577 | -44% | 0% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Relationship | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $6.95 | 1,000 | Director | 1,000 | 2015-08-24 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Relationship | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $3.28 | 22,183 | Officer | 159,724 | 2025-02-04 | Filing | |
| $3.28 | 19,348 | Officer | 106,194 | 2025-02-04 | Filing | |
| $3.28 | 23,790 | Officer, Director | 1,481,003 | 2025-02-04 | Filing | |
| $3.28 | 11,333 | Officer | 86,244 | 2025-02-04 | Filing | |
| $3.69 | 8,846 | Director | 46,069 | 2024-08-14 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 200,757 | $700,630 | 0% | |
| 2. | 10,000 | $34,900 | 0% | |
| 3. | 831 | $2,900 | 0% | |
| 4. | 500 | $1,745 | 0% | |
| 5. | 266 | $926 | 0% |
News See All
Jim Cramer's Lightning Round: 7 Stocks Under the Spotlight
Jim Cramer, the host of Mad Money, offered his insights into the market's recent performance, highlighting why the tech-heavy Nasdaq failed to make a strong rebound.
Here’s Why Arbutus (ABUS) Surged in Q3
Tourlite Capital Management, an investment management firm, released its third quarter 2024 investor letter, a copy of which can be downloaded here.
Arbutus Biopharma Corporation (NASDAQ:ABUS) Q3 2024 Earnings Call Transcript
Arbutus Biopharma Corporation (NASDAQ:ABUS) Q3 2024 Earnings Call Transcript November 6, 2024Arbutus Biopharma Corporation reports earnings inline with expectations.
10 Best Debt-Free Penny Stocks to Buy Now
Inflation in the U.S. has dropped to the lowest level since 2021, setting the stage for the Federal Reserve to cut interest rates.
Arbutus Biopharma Corporation (NASDAQ:ABUS) Q2 2024 Earnings Call Transcript
Operator: Good day, and thank you for standing by. Welcome to the Arbutus Biopharma 2024 Second Quarter Financial Results and Corporate Update. [Operator Instructions].
Arbutus Biopharma Corporation (NASDAQ:ABUS) Q1 2024 Earnings Call Transcript
Arbutus Biopharma Corporation misses on earnings expectations. Reported EPS is $-0.10178 EPS, expectations were $-0.1.
Arbutus Biopharma Corporation (NASDAQ:ABUS) Q4 2023 Earnings Call Transcript
Arbutus Biopharma Corporation reports earnings inline with expectations. Reported EPS is $-0.12 EPS, expectations were $-0.12.
Arbutus Biopharma Corporation (NASDAQ:ABUS) Q3 2023 Earnings Call Transcript
Operator: Good day, and thank you for standing by. Welcome to the Arbutus Third Quarter Corporate and Financial Update Conference Call.
12 Best Micro Cap Stocks To Invest In
In this piece, we will take a look at the 12 best micro cap stocks to invest in.
Billionaire Hedge Funds
